Business Development Challenges for Small & Mid-Sized CROs

Isidora Madic
Feb 13
5 min read

Updated: 2 hours ago

A practical guide to growth, differentiation, and client acquisition in early-phase clinical research

Small and mid-sized Contract Research Organizations (CROs) play a critical role in the life sciences ecosystem. They bring scientific depth, operational flexibility, and therapeutic focus that many sponsors actively seek, especially in early-phase clinical development.

Yet despite strong delivery capabilities, many CROs struggle with business development.

Not because they don’t provide quality services t, but because commercial strategy, lead generation, and structured sales execution are often underdeveloped or inconsistent.

This article explores the most common business development challenges for CROs, why early-phase focus creates a strategic advantage, and how small and mid-sized CROs can build a sustainable CRO growth strategy without trying to compete head-to-head with global players.

The Reality of Business Development for CROs Today

For many small and mid-sized CROs, growth depends heavily on:

Existing sponsor relationships
Referrals
Founder-led selling

While this can work in the early years, it rarely scales.

Business development for CROs today requires structure, positioning, and focus, especially as competition increases and sponsor expectations evolve.

Key Business Development Challenges for Small & Mid-Sized CROs

1. Limited or No In-House Sales Team

Many CROs simply don’t have a dedicated sales function.

Business development is often handled by:

Scientific leadership
Operations managers
Founders or CEOs

This creates an immediate constraint:

No systematic prospecting
No consistent follow-up
No defined CRO sales strategy

Without a clear CRO commercial strategy, pipeline development becomes reactive rather than intentional.

2. One-Person BD Teams Stretched Too Thin

When CROs do hire a BD professional, it’s often a single individual responsible for everything:

Lead generation
Account management
Proposal coordination
Conferences and networking

This role quickly becomes unsustainable.

Without clear prioritization and process, even strong BD talent struggles to deliver consistent results - especially in long, complex CRO sales cycles.

3. Scientific Founders Doing Sales Without Structure

Many CRO founders come from clinical operations or scientific backgrounds—and that expertise is invaluable.

However, scientific credibility alone is not a CRO business development strategy.

Common issues include:

No defined Ideal Customer Profile (ICP)
No segmentation by trial phase or therapeutic area
Inconsistent messaging across outreach

This often leads to missed opportunities and inefficient CRO client acquisition.

4. Long CRO Sales Cycles

CRO sales cycles are inherently long.

Sponsors need time to:

Secure funding
Align internal stakeholders
Finalize protocols
Compare vendors

Without structured follow-up and pipeline management, opportunities quietly disappear.

This is one of the most underestimated challenges in CRO lead generation and sales execution.

5. Difficulty Competing with Global CROs

Small CROs often believe they are losing deals because they are “too small.”

In reality, the problem is usually positioning, not size.

Global CROs dominate:

Phase III programs
Large multinational trials
Full-service mandates

Trying to compete in those segments is rarely an effective CRO growth strategy for smaller organizations.

6. Lack of Clear Differentiation

Many CROs describe themselves as:

Flexible
High quality
Client-focused

While true, these claims are not differentiators.

Without a clearly articulated value proposition, CRO marketing and sales efforts blend into the background - making it harder for sponsors to understand why they should engage.

Why Early-Phase Focus Is a Winning Strategy for CROs

Phase I and II Trials Are Led by Small & Mid-Sized Biotechs

Early-phase development is largely driven by:

Emerging biotech companies
Virtual biotechs
Spin-offs from academia

These sponsors often prefer specialized CROs that can move fast, adapt, and provide hands-on scientific collaboration.

This is where small CROs can outperform larger competitors.

Early-Phase Sponsors Value Expertise and Agility, Not Size

In Phase I and II:

Decision-making is faster
Scientific dialogue matters more than scale
Access to senior CRO leadership is valued

A focused CRO business development strategy aligned with early-phase trials creates stronger conversion rates and repeat business.

Phase III Trials Are Dominated by Global CROs

Large-scale Phase III programs require:

Global infrastructure
Large operational teams
Extensive regulatory coverage

For most small CROs, competing here drains resources without delivering predictable growth.

Early-Phase Trials Enable Long-Term Partnerships

Early success creates momentum:

Proof-of-concept trials
Extension studies
Follow-on programs

This makes early-phase work a powerful engine for sustainable CRO growth strategy, not just short-term revenue.

Ideal Target Clients for Small & Mid-Sized CROs

A successful CRO commercial strategy starts with focus.

High-fit sponsor profiles include:

Pre-Clinical to Phase II Biotech Companies

Limited internal clinical operations
High reliance on external expertise
Need for strategic guidance

Virtual Biotech Companies

Outsourced-by-design operating models
Strong alignment with specialized CRO services

Academic Spin-Offs

Scientifically innovative
Often unfamiliar with CRO selection processes

Medical Device Startups

Niche protocols
Smaller, agile trials

Emerging Pharma Without Internal Clinical Ops

Require operational partners, not vendors

Defining and prioritizing these segments is essential for effective CRO client acquisition.

Importance of Therapeutic Area Alignment

Sponsors Choose CROs Based on Disease Expertise

Therapeutic alignment is one of the strongest decision drivers in CRO selection.

Sponsors want partners who:

Understand disease biology
Know relevant endpoints
Anticipate operational risks

Oncology and CNS Demand Deep Operational Knowledge

Complex indications require:

Experienced project teams
Site networks
Regulatory nuance

Generic messaging fails here.

Rare Disease and Orphan Indications Favor Specialized CROs

Small patient populations, adaptive designs, and biomarker-driven trials reward specialization.

This is a natural advantage for niche CROs with focused experience.

Biomarker and Translational Expertise Is a Differentiator

CROs that can connect:

Clinical operations
Biomarkers
Translational science

Position themselves as strategic partners - not just service providers.

Align Messaging with Sponsor Pipelines

Effective CRO marketing and sales efforts start with:

Understanding sponsor pipelines
Referencing active indications
Speaking the sponsor’s scientific language

This dramatically improves engagement and response rates.

Strategic Partnerships as a CRO Growth Lever

Partnering with Complementary CROs

Instead of building everything in-house, CROs can:

Collaborate with specialists
Extend service offerings
Remain focused

Offering Integrated Services Without Becoming a Large CRO

Strategic partnerships allow CROs to:

Offer end-to-end solutions
Maintain agility
Avoid operational bloat

Building Referral Ecosystems

Trusted referral networks create:

Warm introductions
Higher-quality leads
Shorter sales cycles

Creating “Virtual Full-Service” Models

Sponsors increasingly accept modular service models, if execution is seamless.

This approach strengthens credibility without sacrificing specialization.

Why Outsourced Business Development Makes Sense for CROs

For many organizations, outsourced business development for CROs is a strategic choice, not a compromise.

Cost-Effective Alternative to Internal Sales Teams

No long hiring cycles
No fixed overhead
Immediate execution

Access to Established Life Sciences Networks

Experienced BD partners bring:

Existing sponsor relationships
Market insight
Real-time feedback

Structured CRO Lead Generation and Qualification

Outsourced teams implement:

ICP definition
Account-based targeting
CRM-driven follow-up

This transforms how CROs get new clients.

Also, prospecting works best when embedded within a structured commercial strategy. That’s where a fractional business development partner can align outreach, positioning and partnership strategy.